| __timestamp | Grifols, S.A. | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 660772000 | 9335772 |
| Thursday, January 1, 2015 | 736435000 | 12390000 |
| Friday, January 1, 2016 | 775266000 | 25602000 |
| Sunday, January 1, 2017 | 860348000 | 21262000 |
| Monday, January 1, 2018 | 814775000 | 28430000 |
| Tuesday, January 1, 2019 | 942821000 | 40849000 |
| Wednesday, January 1, 2020 | 985616000 | 60210000 |
| Friday, January 1, 2021 | 1061508000 | 83664000 |
| Saturday, January 1, 2022 | 1190423000 | 104097000 |
| Sunday, January 1, 2023 | 1254234000 | 106916000 |
Unleashing insights
In the competitive world of pharmaceuticals and biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Grifols, S.A., a global leader in plasma-derived medicines, and Iovance Biotherapeutics, Inc., a pioneer in cell therapy, offer a fascinating study in contrasts. From 2014 to 2023, Grifols consistently reported higher SG&A expenses, peaking at approximately $1.25 billion in 2023. This represents a 90% increase over the decade, reflecting its expansive global operations. In contrast, Iovance's SG&A expenses grew from $9 million to $107 million, a staggering 1,046% increase, indicative of its aggressive growth strategy in the biotech sector. While Grifols' expenses are higher in absolute terms, Iovance's rapid percentage growth highlights its dynamic expansion. This comparison underscores the diverse strategies companies employ to optimize costs while pursuing growth.
Comparing SG&A Expenses: AbbVie Inc. vs Grifols, S.A. Trends and Insights
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Grifols, S.A.
Cost Management Insights: SG&A Expenses for argenx SE and Iovance Biotherapeutics, Inc.
BioMarin Pharmaceutical Inc. vs Grifols, S.A.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Grifols, S.A.
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Breaking Down SG&A Expenses: Grifols, S.A. vs TG Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and MorphoSys AG
Grifols, S.A. and Agios Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Verona Pharma plc vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
Bausch Health Companies Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Iovance Biotherapeutics, Inc.